Therapy Areas: Infectious Diseases
IncellDx wins US Patent for use of CCR5 antagonist maraviroc in treating COVID-19
24 November 2021 -

Precision medicine company IncellDx reported on Tuesday the receipt of the US Patent from the US Patent and Trademark Office (USPTO) for methods of treating coronaviruses including COVID-19.

This US patent, which has been assigned the US Patent No. 11,180, 491, underwent expedited review under the USPTO's COVID-19 Prioritized Examination Pilot Programme, according to the company.

The company's patent is supported by studies of CCR5 antagonism in acute COVID-19 and in chronic COVID, known as long COVID or post-acute sequelae of COVID-19. In multiple studies, including a study published in International Journal of Infectious Diseases, the CCR5 antagonism normalized immunologic biomarkers including cytokines and signaling proteins and restored levels of immune cell subsets.

In conjunction, the partnership between the company's Chronic COVID Treatment Center and ARISE MD Integrative Medicine & Surgery will evaluate the use of CCR5 antagonists in randomized, placebo controlled trial as novel therapeutic approach in treating chronic COVID.